<p>, /PRNewswire/ -- Gross Law Firm 向 <strong>ImmunityBio, Inc. (NASDAQ: IBRX)</strong> 的股东发布以下通知。</p>
<p>在列出的诉讼期间内购买 IBRX 股票的股东被鼓励与本事务所联系，以讨论可能的首席原告任命。被任命为首席原告并不是参与任何赔偿的必要条件。</p>
<p>联系我们：</p>
<p>https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<p>** 诉讼期间：**2026 年 1 月 19 日至 2026 年 3 月 24 日</p>
<p><strong>指控：</strong> 起诉书指控在诉讼期间，被告发布了实质性虚假和/或误导性陈述，并/或未能披露以下内容：（1）被告 Soon-Shion 实质性夸大了 Anktiva 的能力；（2）因此，被告关于 ImmunityBio 的业务、运营和前景的陈述在所有相关时间都是实质性虚假和误导的，且/或缺乏合理依据。</p>
<p><strong>截止日期：2026 年 5 月 26 日</strong> 股东不应延迟注册此集体诉讼。请在此注册您的信息： https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<p><strong>股东的下一步：</strong> 一旦您注册为在上述时间段内购买 IBRX 股票的股东，您将被纳入一个投资组合监控软件，以便在案件生命周期内为您提供状态更新。申请成为首席原告的截止日期为 2026 年 5 月 26 日。参与此案件对您没有费用或义务。</p>
<p><strong>为什么选择 Gross Law Firm？</strong> Gross Law Firm 是一家全国知名的集体诉讼律师事务所，我们的使命是保护所有因欺诈、诈骗和非法商业行为而遭受损失的投资者的权利。Gross Law Firm 致力于确保公司遵循负责任的商业实践并参与良好的企业公民行为。该事务所代表因公司发布虚假和/或误导性陈述或遗漏重要信息而导致公司股票人为膨胀而遭受损失的投资者寻求赔偿。律师广告。以往的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Gross Law Firm</p>
<p>15 West 38th Street, 12th floor</p>
<p>New York, NY, 10018</p>
<p>电子邮件：[email protected]</p>
<p>电话： (646) 453-8903</p>
<p>来源：Gross Law Firm</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz"/></p>

IBRX

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

IBBQ

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

标普生物技术 3 倍做空 - Direxion

<p>Gross 律师事务所提醒 ImmunityBio, Inc.（纳斯达克代码：IBRX）股东，集体诉讼的主要原告截止日期为 2026 年 5 月 26 日。购买了 2026 年 1 月 19 日至 2026 年 3 月 24 日期间股票的股东，鼓励注册以争取潜在的主要原告任命，原因是公司被指控发表误导性声明。参与此案件不产生任何费用</p>

<p>, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of <strong>ImmunityBio, Inc. (NASDAQ: IBRX).</strong></p>
<div class="lb-trans"><p>, /PRNewswire/ -- Gross Law Firm 向 <strong>ImmunityBio, Inc. (NASDAQ: IBRX)</strong> 的股东发布以下通知。</p>
</div><p>Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.</p>
<div class="lb-trans"><p>在列出的诉讼期间内购买 IBRX 股票的股东被鼓励与本事务所联系，以讨论可能的首席原告任命。被任命为首席原告并不是参与任何赔偿的必要条件。</p>
</div><p>CONTACT US HERE:</p>
<div class="lb-trans"><p>联系我们：</p>
</div><p>https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<div class="lb-trans"><p>https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
</div><p><strong>CLASS PERIOD:</strong> January 19, 2026 to March 24, 2026</p>
<div class="lb-trans"><p>** 诉讼期间：**2026 年 1 月 19 日至 2026 年 3 月 24 日</p>
</div><p><strong>ALLEGATIONS:</strong> The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendant Soon-Shion materially overstated Anktiva's capabilities; and (2) as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.</p>
<div class="lb-trans"><p><strong>指控：</strong> 起诉书指控在诉讼期间，被告发布了实质性虚假和/或误导性陈述，并/或未能披露以下内容：（1）被告 Soon-Shion 实质性夸大了 Anktiva 的能力；（2）因此，被告关于 ImmunityBio 的业务、运营和前景的陈述在所有相关时间都是实质性虚假和误导的，且/或缺乏合理依据。</p>
</div><p><strong>DEADLINE: May 26, 2026</strong> Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<div class="lb-trans"><p><strong>截止日期：2026 年 5 月 26 日</strong> 股东不应延迟注册此集体诉讼。请在此注册您的信息： https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
</div><p><strong>NEXT STEPS FOR SHAREHOLDERS:</strong> Once you register as a shareholder who purchased shares of IBRX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 26, 2026. There is no cost or obligation to you to participate in this case.</p>
<div class="lb-trans"><p><strong>股东的下一步：</strong> 一旦您注册为在上述时间段内购买 IBRX 股票的股东，您将被纳入一个投资组合监控软件，以便在案件生命周期内为您提供状态更新。申请成为首席原告的截止日期为 2026 年 5 月 26 日。参与此案件对您没有费用或义务。</p>
</div><p><strong>WHY GROSS LAW FIRM?</strong> The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>为什么选择 Gross Law Firm？</strong> Gross Law Firm 是一家全国知名的集体诉讼律师事务所，我们的使命是保护所有因欺诈、诈骗和非法商业行为而遭受损失的投资者的权利。Gross Law Firm 致力于确保公司遵循负责任的商业实践并参与良好的企业公民行为。该事务所代表因公司发布虚假和/或误导性陈述或遗漏重要信息而导致公司股票人为膨胀而遭受损失的投资者寻求赔偿。律师广告。以往的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>The Gross Law Firm</p>
<div class="lb-trans"><p>Gross Law Firm</p>
</div><p>15 West 38th Street, 12th floor</p>
<div class="lb-trans"><p>15 West 38th Street, 12th floor</p>
</div><p>New York, NY, 10018</p>
<div class="lb-trans"><p>New York, NY, 10018</p>
</div><p>Email: [email protected]</p>
<div class="lb-trans"><p>电子邮件：[email protected]</p>
</div><p>Phone: (646) 453-8903</p>
<div class="lb-trans"><p>电话： (646) 453-8903</p>
</div><p>SOURCE The Gross Law Firm</p>
<div class="lb-trans"><p>来源：Gross Law Firm</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY65643&amp;Transmission_Id=202605260900PR_NEWS_USPR_____NY65643&amp;DateId=20260526"/></p>

09:00 ETThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

prnewswire

ImmunityBio

Invesco Nasdaq Biotechnology ETF

09:00 ET Gross 律师事务所提醒股东，ImmunityBio, Inc.诉讼的首席原告截止日期为2026年5月26日- IBRX